PEPTICHIP Streamlined identification of tumour neoantigens for personalised ant...
PEPTICHIP Streamlined identification of tumour neoantigens for personalised anti cancer immunotherapy
Immunotherapeutic strategies have emerged as powerful tools to treat many types of cancers. However, the majority of patients still fails to respond to immunotherapies as targetable tumour characteristics vary from patient to pati...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
NEOpTTL
Innovative approach to an Individualised T-Cell Immunotherap...
8M€
Cerrado
PeptiCHIP
Pre-clinical validation and demonstration of PeptiCHIP: an i...
2M€
Cerrado
IJC2018-035223-I
Profiling of neoantigen specific-lymphocyte subsets for pers...
93K€
Cerrado
NeoIDC
Neoantigen Identification with Dendritic Cell Reprogramming
150K€
Cerrado
VACCIBIOME
Cancer Vaccines and Gut Microbiome a rational approach to o...
2M€
Cerrado
IJC2019-040617-I
Computational identification of bona fide immunogenic neoant...
93K€
Cerrado
Información proyecto PeptiCHIP
Duración del proyecto: 24 meses
Fecha Inicio: 2019-09-04
Fecha Fin: 2021-09-30
Líder del proyecto
HELSINGIN YLIOPISTO
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Descripción del proyecto
Immunotherapeutic strategies have emerged as powerful tools to treat many types of cancers. However, the majority of patients still fails to respond to immunotherapies as targetable tumour characteristics vary from patient to patient. Thus, a greater degree of personalisation is required to fine-tune immunotherapies to the specific vulnerabilities of each patient’s tumour. While therapies that target tumour-specific antigens (neoantigens) invoke a strong and specific anti-tumour immune response, we are currently unable to accurately identify patient-specific neoantigens. Current neoantigen identification and purification methods either require impractically large quantities of tumour material or are laborious, expensive, time-consuming (weeks or months) and inaccurate. As part of ERC project PEPTICRAD (2016-2021), Prof. Vincenzo Cerullo at the University of Helsinki has developed a novel microfluidic chip-based device (PeptiCHIP) which condenses the neoantigen purification steps into a single chip capable of accurately analysing minute quantities of human tumour tissue. PeptiCHIP permits cost-effective, rapid, sample-conserving, user-friendly, accurate and standardised tumour neoantigen identification, thereby unleashing the full potential of personalised anti-tumour immunotherapies. In this ERC PoC project, a team of technological and commercial experts will ascertain the technical and commercial viability of the innovative PeptiCHIP device. We will prepare the first steps toward the start-up of a spin-off by defining the most optimal business strategy and model. Furthermore, we will explore the technical potential of the PeptiCHIP and solidify our IP-position. We will develop a solid business strategy based on the technological aspects, the market needs and trends. Finally, during this project we will gain technical and commercial proof-of-concept, providing the necessary information for potential commercialisation routes.